We are developing therapies that, administered just once, have the potential to transform the lives of people with severe genetic and rare diseases and cancer. Our current platform is just the beginning. We are committed to continuing to develop gene therapy technologies and capabilities that have broad potential beyond the core indications.
We are actively seeking collaborators and licensing opportunities in the U.S. and around the world to explore the therapeutic potential of our technologies in new cell types and diseases.
We are actively seeking collaborators, in- and out-licensing opportunities to fully leverage the transformational therapeutic potential of our platforms. Specific areas of interest include:
bluebird bio and Celgene are also working together on a second clinical-stage anti-BCMA CAR T program, bb21217.
In December 2017, we entered into a strategic research collaboration and licensing agreement with TC BioPharm to discover and develop gamma delta CAR T cell product candidates for cancer immunotherapy.
Under the terms of the agreement, TC BioPharm is responsible for development of all targets through Phase 1/2, at which point we have the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.
In June 2016, we entered into a strategic manufacturing agreement with Lonza Houston, Inc., providing for the future commercial production of our Lenti-D™ and LentiGlobin™ drug products.
This agreement follows a successful multi-year clinical manufacturing relationship and provides us with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. Under this multi-year agreement, Lonza will complete the suite design, construction and validation along with process validation prior to anticipated commercial launch.
In December 2016, we entered into a strategic manufacturing agreement with apceth Biopharma for the future European commercial production of our Lenti-D™ product candidate for cerebral adrenoleukodystrophy and our LentiGlobin™ product candidate for transfusion-dependent β-thalassemia.
Under this multi-year agreement, apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for LentiGlobin and Lenti-D drug product to support the treatment of European patients with transfusion-dependent beta thalassemia and cerebral adrenoleukodystrophy, respectively. This agreement follows a successful multi-year manufacturing relationship and provides us with European commercial manufacturing capabilities, including dedicated production suites within apceth Biopharma’s state-of-the-art GMP facility.